Clinical Outcomes of Secondary Prophylactic Granulocyte Colony-Stimulating Factors in Breast Cancer Patients at a Risk of Neutropenia with Doxorubicin and Cyclophosphamide-Based Chemotherapy
Doxorubicin and cyclophosphamide (AC)-based chemotherapy has been a standard regimen for early-stage breast cancer (ESBC) with an intermediate risk (10–20%) of febrile neutropenia (FN). Secondary prophylaxis of granulocyte colony-stimulating factor (G-CSF) is considered in patients receiving AC-base...
Guardado en:
Autores principales: | Jae Hee Choi, Min Jung Geum, Ji Eun Kang, Nam Gi Park, Yun Kyoung Oh, Sandy Jeong Rhie |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
MDPI AG
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/918773c20d6940ac9234100a7cc7ce1a |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Lipegfilgrastim in the management of chemotherapy-induced neutropenia of cancer patients
por: Guariglia R, et al.
Publicado: (2016) -
Evaluating the Prognostic Role of Monocytopenia in Chemotherapy-Induced Febrile Neutropenia Patients Treated with Granulocyte Colony-Stimulating Factor
por: Alshari O, et al.
Publicado: (2021) -
Reduction of febrile neutropenia by using long-acting granulocyte colony-stimulating factors in patients with solid tumors receiving every-2-week chemotherapy
por: I. B. Kononenko, et al.
Publicado: (2020) -
Neutropenia febril de alto riesgo en leucemia aguda. Experiencia en un hospital público: Programa Nacional de Drogas Antineoplásicas del Adulto (PANDA), Hospital del Salvador, 1991-2001
por: Puga L,Bárbara, et al.
Publicado: (2003) -
DETECTION OF AUTO- AND ALLOANTIBODIES AGAINST GRANULOCYTES BY MEANS OF GEL AGGLUTINATION TECHNIQUE
por: N. V. Mineeva, et al.
Publicado: (2014)